Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT04218071 | Actuate 1901: 9-ING-41 in Myelofibrosis | PHASE2 | COMPLETED | 17 | — | — | Aug 20, 2020 | Jan 18, 2024 | Feb 7, 2024 | 9 | United States |
The percent of patients with response will be assessed at the protocol specified timepoints according to the Revised IWG-MRT and ELN Response Criteria for MF (2013)
| Arm | Type | Description |
|---|---|---|
| 9-ING-41 | EXPERIMENTAL | 9-ING-41 is administered by intravenous infusion twice weekly at a dose of 9.3 mg/kg. Cycle duration is 28 days. |
| 9-ING-41 plus Ruxolitinib | EXPERIMENTAL | 9-ING-41 9.3 mg/kg will be administered by intravenous infusion twice weekly for cycle durations of 28 days with Ruxolitinib at doses specified in the protocol as appropriate for patient's platelet count. |
| Name | Type | Description |
|---|---|---|
| Ruxolitinib | DRUG | Ruxolitinib at protocol-specified doses for given platelet count |
| 9-ING-41 | DRUG | 9- |
Inclusion Criteria: Patient - 1. Is able to understand and voluntarily sign a written informed consent and is willing and able to comply with the protocol requirements including scheduled visits, treatment plan, laboratory tests and other study procedures 2. Is aged ≥ 18 years 3. Has documented di...